Acadian Asset Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.86M | Buy |
18,704
+25
| +0.1% | +$3.83K | ﹤0.01% | 849 |
|
|
2025
Q4 | $2.57M | Sell |
18,679
-9,854
| -35% | -$1.29M | ﹤0.01% | 845 |
|
|
2025
Q3 | $3.66M | Buy |
28,533
+233
| +0.8% | +$28.4K | 0.01% | 726 |
|
|
2025
Q2 | $3.42M | Sell |
28,300
-68
| -0.2% | -$7.66K | 0.01% | 683 |
|
|
2025
Q1 | $3.16M | Sell |
28,368
-9,406
| -25% | -$1M | 0.01% | 630 |
|
|
2024
Q4 | $3.67M | Sell |
37,774
-3,521
| -9% | -$375K | 0.01% | 605 |
|
|
2024
Q3 | $4.75M | Buy |
41,295
+11,301
| +38% | +$1.28M | 0.01% | 517 |
|
|
2024
Q2 | $3.19M | Buy |
29,994
+16,335
| +120% | +$1.64M | 0.01% | 628 |
|
|
2024
Q1 | $1.32M | Sell |
13,659
-34,499
| -72% | -$3.54M | ﹤0.01% | 773 |
|
|
2023
Q4 | $4.86M | Buy |
48,158
+34,228
| +246% | +$3.3M | 0.02% | 466 |
|
|
2023
Q3 | $1.42M | Buy |
13,930
+1,130
| +9% | +$115K | 0.01% | 777 |
|
|
2023
Q2 | $1.29M | Buy |
+12,800
| New | +$1.28M | 0.01% | 820 |
|
|
2023
Q1 | – | Sell |
-458
| Closed | -$41K | – | 1897 |
|
|
2022
Q4 | $41K | Buy |
+458
| New | +$38.6K | ﹤0.01% | 1604 |
|
|
2022
Q3 | – | Sell |
-884
| Closed | -$75K | – | 1788 |
|
|
2022
Q2 | $75K | Buy |
+884
| New | +$77.6K | ﹤0.01% | 1415 |
|
|
2022
Q1 | – | Sell |
-428
| Closed | -$37K | – | 1743 |
|
|
2021
Q4 | $37K | Sell |
428
-2,116
| -83% | -$176K | ﹤0.01% | 1530 |
|
|
2021
Q3 | $208K | Sell |
2,544
-1,886
| -43% | -$170K | ﹤0.01% | 1285 |
|
|
2021
Q2 | $404K | Buy |
4,430
+841
| +23% | +$74.9K | ﹤0.01% | 1216 |
|
|
2021
Q1 | $307K | Buy |
3,589
+1,217
| +51% | +$109K | ﹤0.01% | 1357 |
|
|
2020
Q4 | $224K | Buy |
+2,372
| New | +$207K | ﹤0.01% | 1511 |
|
|
2020
Q2 | – | Sell |
-755
| Closed | -$62K | – | 2301 |
|
|
2020
Q1 | $62K | Buy |
755
+144
| +24% | +$12.8K | ﹤0.01% | 1464 |
|
|
2019
Q4 | $58K | Buy |
+611
| New | +$54.8K | ﹤0.01% | 1583 |
|
|
2019
Q1 | – | Sell |
-276
| Closed | -$21K | – | 2014 |
|
|
2018
Q4 | $21K | Sell |
276
-18,238
| -99% | -$1.42M | ﹤0.01% | 1554 |
|
|
2018
Q3 | $1.43M | Hold |
18,514
| – | – | 0.01% | 639 |
|
|
2018
Q2 | $1.25M | Hold |
18,514
| – | – | 0.01% | 679 |
|
|
2018
Q1 | $1.34M | Hold |
18,514
| – | – | 0.01% | 676 |
|
|
2017
Q4 | $1.39M | Hold |
18,514
| – | – | 0.01% | 633 |
|
|
2017
Q3 | $1.42M | Hold |
18,514
| – | – | 0.01% | 618 |
|
|
2017
Q2 | $1.39M | Hold |
18,514
| – | – | 0.01% | 648 |
|
|
2017
Q1 | $1.23M | Sell |
18,514
-928
| -5% | -$61.8K | 0.01% | 730 |
|
|
2016
Q4 | $1.27M | Buy |
19,442
+928
| +5% | +$60.2K | 0.01% | 681 |
|
|
2016
Q3 | $1.31M | Hold |
18,514
| – | – | 0.01% | 634 |
|
|
2016
Q2 | $1.37M | Sell |
18,514
-499
| -3% | -$34.5K | 0.01% | 579 |
|
|
2016
Q1 | $1.23M | Buy |
+19,013
| New | +$1.29M | 0.01% | 614 |
|
|
2015
Q3 | – | Sell |
-1,088
| Closed | -$96K | – | 1391 |
|
|
2015
Q2 | $96K | Sell |
1,088
-205
| -16% | -$18.8K | ﹤0.01% | 1020 |
|
|
2015
Q1 | $114K | Sell |
1,293
-939
| -42% | -$83.3K | ﹤0.01% | 999 |
|
|
2014
Q4 | $185K | Sell |
2,232
-1,296
| -37% | -$107K | ﹤0.01% | 897 |
|
|
2014
Q3 | $298K | Buy |
3,528
+1,207
| +52% | +$97.7K | ﹤0.01% | 728 |
|
|
2014
Q2 | $188K | Buy |
2,321
+1,380
| +147% | +$109K | ﹤0.01% | 795 |
|
|
2014
Q1 | $72K | Buy |
+941
| New | +$68.6K | ﹤0.01% | 869 |
|
|
2013
Q4 | – | Sell |
-934
| Closed | -$64K | – | 1082 |
|
|
2013
Q3 | $64K | Hold |
934
| – | – | ﹤0.01% | 869 |
|
|
2013
Q2 | $59K | Buy |
+934
| New | +$60.8K | ﹤0.01% | 798 |
|
Other funds holding NVS
Acadian Asset Management's NVS Position: Q1 2026 in Review
Acadian Asset Management increased its Novartis (NVS) stake by 0.13% in Q1 2026, buying an estimated $3.83K and bringing the position to 18,704 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #849.
Acadian Asset Management first reported a position in NVS in Q2 2013 and has held it in 41 quarters since. The position peaked at $4.86M in Q4 2023. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Acadian Asset Management held 18,704 shares of Novartis worth $2.86M as of Q1 2026.
- Acadian Asset Management bought 25 Novartis shares in Q1 2026, an estimated $3.83K.
- Novartis made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #849 holding.
- Acadian Asset Management first reported a position in Novartis in Q2 2013 and has held it in 41 quarters since.
- Acadian Asset Management's Novartis position peaked at $4.86M in Q4 2023.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.